Proactive Investors
07 Aug 2026, 06:46 UTC · 1h ago
Oxford Biomedica cuts 2026 revenue guidance as clients delay orders
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Proactive Investors
07 Aug 2026, 06:46 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Oxford BioMedica (OXB) has lowered its 2026 revenue guidance to between £180 million and £200 million. — A downward revision of revenue guidance typically leads to a negative price reaction as it suggests slower near-term growth.
-0.60The company expects 2026 EBITDA margins to be in the mid-single digits (excluding one-off costs) or low-single digits on a reported basis. — Low single-digit margins indicate tight profitability and reduced earnings potential for the fiscal year.
-0.40OXB's Durham, North Carolina site suffered a six-month integration delay, though the first manufacturing run has now commenced. — Operational delays in capacity expansion signal execution risk and deferred revenue generation.
-0.30Continue reading
6 related stories
Top 2 movers · tap to explore
The company's new business pipeline grew 30% year-on-year to approximately $713 million. — Strong pipeline growth suggests healthy long-term demand despite current short-term guidance cuts.
+0.30OXB maintained its medium-term targets, including 25-30% revenue growth for 2027 and a £500 million revenue goal by 2030. — Management's confidence in long-term targets mitigates some of the immediate negative impact of the 2026 guidance cut.
+0.20Which stocks this story touches
The company cut its 2026 revenue guidance due to deferred client orders and delays in bringing a US site online.
The company is mentioned in the context of an interview about leadership and the subscription economy, providing no material financial news.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Barrons
2h ago
